# OnCo record minoxidil-chemotherapy-alopecia (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "minoxidil-chemotherapy-alopecia" ;
  schema:name "Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss"@en ;
  schema:description "Most hair grows back after chemotherapy, but a minority, especially after docetaxel, are left with thin hair, and tamoxifen and aromatase inhibitors cause gradual thinning. Minoxidil lotion or low-dose tablets, the same treatment used for pattern hair loss, improved regrowth in most patients in dermatology series and shortened regrowth time in an early randomised trial."@en ;
  schema:url <https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Minoxidil> ;
  schema:citation <https://doi.org/10.1016/s0190-9622(96)90500-9>, <https://doi.org/10.1001/jamadermatol.2018.0454>, <https://doi.org/10.1016/j.jaad.2018.03.056> ;
  onco:status "emerging" ;
  onco:tag "complementary", "supportive-care", "evidence:moderate" ;
  onco:related <https://onco.cc/ideas/idea-moon-hair-preservation-for-all/>, <https://onco.cc/technologies/hair-platelet-rich-plasma/>, <https://onco.cc/technologies/hair-photobiomodulation/>, <https://onco.cc/technologies/hair-antiandrogens-alopecia/>, <https://onco.cc/technologies/hair-supplements-marketed/>, <https://onco.cc/technologies/hair-topical-prevention-agents/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/scalp-cooling/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/exemestane/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:terms <https://onco.cc/terms/aromatase-inhibitor/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-freites-martinez-jama-dermatol/>, <https://onco.cc/key-papers/paper-freites-martinez-j-am-acad-dermatol/>, <https://onco.cc/key-papers/paper-duvic-j-am-acad-dermatol/> .